Auranofin exerts antibacterial activity against Neisseria gonorrhoeae in a female mouse model of genital tract infection

Simple item page
dc.contributor.authorElhassanny, Ahmed E. M.en
dc.contributor.authorAbutaleb, Nader S.en
dc.contributor.authorSeleem, Mohamed N.en
dc.date.accessioned2022-08-24T17:13:04Zen
dc.date.available2022-08-24T17:13:04Zen
dc.date.issued2022-04-21en
dc.description.abstractNeisseria gonorrhoeae has been classified by the U.S. Centers for Disease Control and Prevention as an urgent threat due to the rapid development of antibiotic resistance to currently available antibiotics. Therefore, there is an urgent need to find new antibiotics to treat gonococcal infections. In our previous study, the gold-containing drug auranofin demonstrated potent in vitro activity against clinical isolates of N. gonorrhoeae, including multidrug-resistant strains. Therefore, the aim of this study was to investigate the in vivo activity of auranofin against N. gonorrhoeae using a murine model of vaginal infection. A significant reduction in N. gonorrhoeae recovered from the vagina was observed for infected mice treated with auranofin compared to the vehicle over the course of treatment. Relative to the vehicle, after three and five days of treatment with auranofin, a 1.04 (91%) and 1.40 (96%) average log(10)-reduction of recovered N. gonorrhoeae was observed. In conclusion, auranofin has the potential to be further investigated as a novel, safe anti-gonococcal agent to help meet the urgent need for new antimicrobial agents for N. gonorrhoeae infection.en
dc.description.notesM.N.S. received funding from National Institutes of Health (Grant No. R01AI130186) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.en
dc.description.sponsorshipNational Institutes of Health [R01AI130186]en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0266764en
dc.identifier.issn1932-6203en
dc.identifier.issue4en
dc.identifier.othere0266764en
dc.identifier.pmid35446884en
dc.identifier.urihttp://hdl.handle.net/10919/111619en
dc.identifier.volume17en
dc.language.isoenen
dc.publisherPLOSen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectantimicrobial resistanceen
dc.subjectrepurposing auranofinen
dc.subjectgonococcal-infectionen
dc.subjectimmune-responsesen
dc.subjectgold compounden
dc.subjectin-vitroen
dc.subjectefficacyen
dc.subjectsusceptibilityen
dc.subjectmutationsen
dc.subjectmechanismen
dc.titleAuranofin exerts antibacterial activity against Neisseria gonorrhoeae in a female mouse model of genital tract infectionen
dc.title.serialPlos Oneen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
journal.pone.0266764.pdf
Size:
726.2 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Scholarly Works, Biomedical Sciences and Pathobiology
Destination Area: Global Systems Science (GSS)
Scholarly Works, Center for Emerging, Zoonotic, and Arthropod-borne Pathogens (CeZAP)